Inventor · disambiguated record
David Scott Wilson
Also filed as: WILSON DAVID · WILSON DAVID S · WILSON DAVID SCOTT · WILSON JR DAVID S
32 granted patents·28 pending applications·172 citations·filing 2001–2025
97Inventor score
Files withECOLE POLYTECHNIQUE FED LAUSANNE EPFL14TEVA PHARMACEUTICALS AUSTRALIA PTY LTD8ASTRAZENECA AB6UNIV CHICAGO5CEPHALON LLC4
Top patents by PatentIndex Score
60 records- 0197US10046056B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2016·Granted Aug 14, 2018·17 cites·25 claims
- 0296US10953101B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2018·Granted Mar 23, 2021·8 cites·18 claims
- 0396US10946079B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2015·Granted Mar 16, 2021·8 cites·25 claims
- 0496US10940209B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2018·Granted Mar 9, 2021·8 cites·18 claims
- 0595US11801305B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2019·Granted Oct 31, 2023·6 cites·20 claims
- 0693US10821157B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2015·Granted Nov 3, 2020·16 cites·26 claims
- 0791US10232041B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Mar 19, 2019·9 cites·21 claims
- 0890US9636334B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 2, 2017·9 cites·20 claims
- 0989US11253579B2Compositions and methods for inducing immune toleranceUNIV CHICAGO·Filed 2018·Granted Feb 22, 2022·3 cites·18 claims
- 1088US11654188B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2019·Granted May 23, 2023·2 cites·20 claims
- 1188US6841359B2Streptavidin-binding peptides and uses thereofGEN HOSPITAL CORP·Filed 2001·Granted Jan 11, 2005·14 cites·21 claims
- 1287US9963515B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 8, 2018·5 cites·27 claims
- 1387US9611322B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Granted Apr 4, 2017·6 cites·18 claims
- 1486US11793882B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2019·Granted Oct 24, 2023·1 cites·20 claims
- 1586US9505826B2Modified antibody with improved half-lifeWILSON DAVID·Filed 2011·Granted Nov 29, 2016·14 cites·6 claims
- 1684US7138253B2Streptavidin-binding peptides and uses thereofGEN HOSPITAL CORP·Filed 2004·Granted Nov 21, 2006·8 cites·25 claims
- 1783US10981986B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 20, 2021·2 cites·21 claims
- 1882US10906973B2Antibody variants transmigrating the blood-brain barrier and uses thereofNAT RES COUNCIL CANADA·Filed 2017·Granted Feb 2, 2021·3 cites·19 claims
- 1981US11666638B2Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2019·Granted Jun 6, 2023·2 cites·20 claims
- 2080US6720165B2Methods for making antibody fragments and compositions resulting therefromZYOMIX INC·Filed 2001·Granted Apr 13, 2004·15 cites·9 claims
- 2179US2025017930A1Pharmaceutical compositions comprising azd9291ASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 2279US2023115331A1Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2022·Application pending·0 cites
- 2378US2023093483A1Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2022·Application pending·0 cites
- 2478US2023119325A1Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2022·Application pending·0 cites
- 2575US11117975B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2018·Granted Sep 14, 2021·1 cites·13 claims
- 2675US2023108299A1Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2022·Application pending·0 cites
- 2774US11707526B2Polymer hydrogels for in vivo applications and methods for using and preparing sameMURTHY NIREN·Filed 2022·Granted Jul 25, 2023·0 cites·4 claims
- 2874US2025295743A1Glycotargeting therapeuticsECOLE POLYTECHNIQUE FED LAUSANNE EPFL·Filed 2025·Application pending·0 cites
- 2972US12281148B2Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereofCEPHALON LLC·Filed 2024·Granted Apr 22, 2025·0 cites·10 claims
- 3072US10183020B2Pharmaceutical compositions comprising AZD9291ASTRAZENECA AB·Filed 2015·Granted Jan 22, 2019·2 cites·23 claims
- 3171US11253591B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted Feb 22, 2022·0 cites·17 claims
- 3271US7183392B2Site-specific, covalent bioconjugation of proteinsZYOMYX INC·Filed 2001·Granted Feb 27, 2007·13 cites·5 claims
- 3371US2022395502A1Pharmaceutical compositions comprising azd9291ASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 3470US2025114441A1Polymeric vaccine for opioid addictionUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 3568US2024189310A1Pharmaceutical compositions comprising azd9291ASTRAZENECA AB·Filed 2021·Application pending·0 cites
- 3666US2022211826A1Compositions and methods for inducing immune toleranceUNIV CHICAGO·Filed 2022·Application pending·0 cites
- 3766US2024058453A1Click chemistry hydrogel with minimal swelling as a dural sealant and local delivery vehicle for recombinant proteins and other bioactive agentsUNIV VIRGINIA COMMONWEALTH·Filed 2023·Application pending·0 cites
- 3863US11253597B2Polymer hydrogels for in vivo applications and methods for using and preparing sameMURTHY NIREN·Filed 2018·Granted Feb 22, 2022·0 cites·7 claims
- 3963US2020360378A1Pharmaceutical compositions comprising azd9291ASTRAZENECA AB·Filed 2020·Application pending·0 cites
- 4063US2024076343A1Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereofCEPHALON LLC·Filed 2023·Application pending·0 cites
- 4161US2025195677A1Uses for attenuated il-2 immunoconjugatesCEPHALON LLC·Filed 2024·Application pending·0 cites
- 4257US2019111057A1Pharmaceutical compositions comprising azd9291ASTRAZENECA AB·Filed 2018·Application pending·0 cites
- 4357US2008076673A1Engineered binding proteinsZYOMYX INC·Filed 2007·Application pending·0 cites
- 4455US10039831B2Polymer hydrogels for in vivo applications and methods for using and preparing sameMURTHY NIREN·Filed 2012·Granted Aug 7, 2018·0 cites·14 claims
- 4555US2004091957A1Methods for making antibody fragments and compositions resulting therefromZYOMYX INC·Filed 2003·Application pending·0 cites
- 4655US2024150447A1Compositions and methods for increasing transport into the brainCEPHALON LLC·Filed 2023·Application pending·0 cites
- 4754US2014106332A1Method and apparatus for mobile social learningGESSNER RICHARD·Filed 2013·Application pending·0 cites
- 4854US2016367695A1Polypeptide constructs and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 4953US11542339B2Anti-CD43 antibody and use thereof for cancer treatmentAPROGEN MEDICINES INC·Filed 2020·Granted Jan 3, 2023·0 cites·9 claims
- 5053US2022305135A1Methods and compositions for treating cancer with cancer-targeted adjuvantsUNIV CHICAGO·Filed 2020·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →